

[Hydroxycarbamide \(hydroxyurea\)](#)

Not recommended as an essential medicine

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01XX05](#)

Indication

Squamous cell carcinoma of oropharynx ICD11 code: [2C3A.0](#)

INN

Hydroxycarbamide

Medicine type

Chemical agent

List type

Complementary

Formulations

**Oral > Solid:** 200 mg ; 250 mg ; 300 mg ; 400 mg ; 500 mg ; 1 g

EML status history

First added in 2009 ([TRS 958](#))

Removed in 2015 ([TRS 994](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Hydroxycarbamide \(hydroxyurea\)](#)

DrugBank

[Hydroxycarbamide \(Hydroxyurea\)](#)

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of hydroxycarbamide was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for hydroxycarbamide for more information.